Sugi Predict

Sugi Predict / Targets / HCN4

HCN4

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 · Q9Y3Q4 · HCN4 on Sugi Atlas →

3,305 patent compounds predicted against HCN4, 1,758 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4364182 SCHEMBL4364182 0.56 14/20
SCHEMBL4350496 SCHEMBL4350496 0.55 14/20
SCHEMBL4356002 SCHEMBL4356002 0.52 14/20
SCHEMBL4535037 SCHEMBL4535037 0.55 13/20
SCHEMBL4353725 SCHEMBL4353725 0.54 13/20
SCHEMBL4351955 SCHEMBL4351955 0.55 12/20
SCHEMBL7362659 SCHEMBL7362659 0.53 12/20
SCHEMBL7397897 SCHEMBL7397897 0.58 11/20
SCHEMBL4536437 SCHEMBL4536437 0.54 10/20
SCHEMBL4538900 SCHEMBL4538900 0.53 10/20
SCHEMBL7396425 SCHEMBL7396425 0.39 10/20
SCHEMBL4537563 SCHEMBL4537563 0.55 9/20
SCHEMBL4358152 SCHEMBL4358152 0.55 9/20
SCHEMBL7392535 SCHEMBL7392535 0.40 9/20
SCHEMBL7392536 SCHEMBL7392536 0.40 9/20
SCHEMBL2966305 SCHEMBL2966305 0.39 9/20
SCHEMBL4374231 SCHEMBL4374231 0.53 8/20
SCHEMBL4528274 SCHEMBL4528274 0.53 8/20
SCHEMBL2433931 SCHEMBL2433931 0.49 8/20
SCHEMBL1073055 SCHEMBL1073055 0.73 7/20

Clinical trials — most relevant to HCN4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease PHASE4NOT_YET_RECRUITING
Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients PHASE3NOT_YET_RECRUITING
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2 PHASE2RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males PHASE1COMPLETED
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China nanCOMPLETED
Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia nanCOMPLETED
The Natural History of TRPV4 Neuropathy nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Flecainide-Short Long Study (Flec-SL) nanCOMPLETED
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC. nanNOT_YET_RECRUITING
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Measuring Single Neuron Activity in the Brain nanNOT_YET_RECRUITING
Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
Characterization of Complex Pulse Shapes in Deep Brain Stimulation for Movement Disorders Using EEG and Local Field Potential Recordings nanCOMPLETED
Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients? nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a HCN4 binder may also engage these)

ProteinNameSimilarity
Q9JKA7 — 1.000 Q9JKA7 →
Q9TV66 — 1.000 Q9TV66 →
O70507 — 1.000 O70507 →
HCN1 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 0.991 landscape →
Q9MZS1 — 0.990 Q9MZS1 →
Q9JKB0 — 0.990 Q9JKB0 →
Q9TUI4 — 0.989 Q9TUI4 →
O88704 — 0.988 O88704 →
O88703 — 0.987 O88703 →
HCN2 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 0.986 landscape →
O88705 — 0.986 O88705 →
Q9R1T9 — 0.986 Q9R1T9 →
Q9JKA9 — 0.985 Q9JKA9 →
Q03717 — 0.985 Q03717 →
Q8WNY2 — 0.984 Q8WNY2 →
HCN3 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 0.984 landscape →
P58126 — 0.984 P58126 →
O54853 — 0.983 O54853 →
O35219 — 0.983 O35219 →
Q8K3F6 — 0.983 Q8K3F6 →
O88944 — 0.983 O88944 →
KCNH2 Voltage-gated inwardly rectifying potassium channel KCNH2 0.983 landscape →
O08962 — 0.983 O08962 →
O08703 — 0.983 O08703 →
O89047 — 0.982 O89047 →
Q60603 — 0.982 Q60603 →
Q9JKA8 — 0.982 Q9JKA8 →
KCNH3 Voltage-gated inwardly rectifying potassium channel KCNH3 0.981 landscape →
KCNQ2 Potassium voltage-gated channel subfamily KQT member 2 0.981 landscape →
Q9WVJ0 — 0.981 Q9WVJ0 →